Role of NGS in acute leukemias

Torsten Haferlach, MD, PhD, MLL Munich Leukemia Laboratory, Munich, Germany, discusses the use of next-generation sequencing (NGS) in the diagnosis, follow-up and minimal residual disease measurement of patients with acute leukemias, and how NGS, a rapidly changing field, is an important tool in implementing precision medicine in hematological oncology. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).